drugset
drugset / Trial / NCT06333977

A Study of LC542019 in Healthy Subjects and Subjects With T2DM

NCT06333977 ↗

Phase 1 Completed 100 enrolled LG Chem
RandomizedSequentialDouble-blindTreatment

Summary

to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics in healthy subjects and subjects with type 2 diabetes (T2DM).

Timeline

Start
2022-03-25
Primary completion
2023-12-14
Completion
2023-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject LC542019 Unknown — Oral

Indications

type 2 diabetes mellitus